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This study used linked, routinely‑collected datasets to explore incidence, clinical characteristics 
and outcomes of prostate cancer (PC) patients who experience a rise in prostate‑specific antigen 
(PSA) levels despite androgen deprivation therapy (ADT), without evidence of metastases in their 
patient record, termed non‑metastatic castration‑resistant PC (nmCRPC). Routinely collected 
administrative data in Wales were used to identify patients diagnosed with PC and nmCRPC from 
2000–2015. Logrank tests and Cox proportional hazard models were used to compare time‑to‑events 
across subgroups defined by PSA doubling time and age. Of 38,021 patients identified with PC, 1,465 
met nmCRPC criteria. PC incidence increased over the study period, while nmCRPC categorizations 
reduced. Median time from PC diagnosis to nmCRPC categorization was 3.07 years (95% confidence 
interval [CI] 2.91–3.26) and from nmCRPC categorization to metastases/death was 2.86 years (95% CI 
2.67–3.09). Shorter PSA doubling time (≤ 10 months, versus > 10 months) was associated with reduced 
time to metastases or death (2.11 years [95% CI 1.92–2.30] versus 5.22 years [95% CI 4.87–5.51]). Age 
was not significantly associated with time to metastases/death. Our findings highlight key clinical 
characteristics and outcomes for patients with nmCRPC prior to the introduction of recently approved 
treatments.
Prostate cancer (PC) is the second most frequent malignancy in men worldwide, with over 48,000 incident 
cases in the UK in 2017, 2,705 of which occurred in  Wales1,2. Palliative treatment options for patients with PC 
are based around androgen deprivation therapy (ADT), which initially elicits a response in most patients with 
castration-sensitive prostate cancer (CSPC)3. However, despite an androgen-deprived state, a subset of men 
treated with ADT subsequently experience rising prostate-specific antigen (PSA) levels, indicating a biochemical 
recurrence or progression of disease termed castration-resistant prostate cancer (CRPC). Typically, this occurs 
with co-existent radiographic evidence of progressive distant metastatic disease (mCRPC). However, transition 
to CRPC may also occur without radiologically detectable distant metastases, classified as non-metastatic CRPC 
(nmCRPC)4.
In combination with ADT, established treatment options for the clinical management of CSPC or mCRPC 
include docetaxel chemotherapy, the androgen synthesis inhibitor therapy abiraterone acetate plus prednisone, 
and the novel androgen receptor antagonists enzalutamide and  apalutamide5–7. Recent data also support the 
use of enzalutamide, apalutamide, and darolutamide in patients with nmCRPC and a PSA doubling time 
of ≤ 10 months, on the basis of a metastasis-free survival  benefit8–10. These relatively recent therapeutic options 
for nmCRPC highlight the importance of documenting accurate real-world incidence, clinical characteristics 
and outcomes to inform treatment needs.
There are, however, very limited data available on the burden of nmCRPC disease outside randomized con-
trolled trials (RCTs; SPARTAN, PROSPER and ARAMIS)8–10. While RCTs are critical to demonstrating the safety 
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and efficacy of new treatments, their design and inclusion criteria, including increased imaging requirements 
and relatively higher risk patients based on PSA doubling time, can affect documented patient outcomes and 
limit generalization to real-world populations. Real-world evidence, using data collected from routine clinical 
settings and registries, can complement RCTs and support their generalization to broader patient groups. Previ-
ous publications exploring nmCRPC and mCRPC in real-world settings have mostly included small samples of 
patients from specific hospitals or data  registries11,12. Recently, a population-based observational study in Sweden 
reported clinical characteristics and outcomes of over 1,700 patients with nmCRPC over 10  years13. To address 
this paucity of data, we undertook a retrospective analysis of an nmCRPC patient cohort using Welsh health 
database records between 2000–2015. We aimed to describe key clinical characteristics and outcomes of this 
patient population and identify potential risk factors for early disease progression or mortality.
Materials (patients) and methods
Study design and data sources. This retrospective observational cohort study was conducted using 
routinely collected administrative data in Wales, including prescriptions, diagnostic procedures and hospital 
admissions, hosted by the Secure Anonymised Information Linkage (SAIL) Databank at Swansea  University14,15. 
The study population denominator was the Welsh Demographics Service (WDS) dataset, containing data for all 
individuals registered with a Welsh general practitioner (GP), including registration start and end  dates16. Clini-
cal information arising from National Health Service (NHS)-funded services (which are free to patients at the 
point of delivery) provided to Welsh residents was derived from Wales Primary Care GPs (WLGP), Welsh Can-
cer Incidence and Surveillance Unit (WCISU) and Patient Episode Dataset for Wales (PEDW). Date and cause of 
death was derived from the Office for National Statistics (ONS) Annual District Deaths Extract (ADDE), which 
includes details of all deaths of Welsh-domiciled residents. Apart from the WLGP dataset, coverage for each 
dataset includes all of Wales, estimated to include approximately 1.5 million males in  201917.
The PEDW and WCISU datasets were used to identify patients with PC using International Classification 
of Diseases (ICD)-10 codes, while the WLGP dataset used Read version 2 codes. Each of these systems act as 
a coded thesaurus of clinical terms to provide standard vocabulary for clinicians; the ICD system is globally 
 recognized18 while the Read system is used primarily within the  NHS19. An algorithm, implemented at two 
levels of stringency, was designed to identify nmCRPC cases based on the presence (in the GP record) of codes 
for receipt of ADT (luteinizing hormone-releasing hormone [LHRH] analogue, LHRH antagonist or bilateral 
surgical castration), PSA test results and codes indicating presence or absence of metastatic disease. Full details 
on dataset use are available in the supplementary material.
Patients. This analysis features three nested patient cohorts identified from the linked datasets: a PC cohort, 
the ‘main nmCRPC cohort’, and a ‘stringent nmCRPC cohort’, based on supplementary inclusion criteria to 
those used for the main nmCRPC cohort. The stringent nmCRPC subset was used to validate results from the 
main nmCRPC cohort, given that explicit non-metastatic PEDW codes were not available for many patients and 
most diagnoses were inferred from available medical records.
The PC cohort had a diagnosis of PC made between 01 January 2000 and 31 December 2015. Follow-up data 
were available until 31 March 2018. The main nmCRPC cohort included all patients from the PC cohort with ≥ 1 
period of ADT in their GP history after PC diagnosis and at least three subsequently increasing PSA measure-
ments that met the Prostate Cancer Working Group 2 criteria for PSA  progression20. These criteria required two 
rises in PSA values with ≥ 1 week between readings and a final reading ≥ 2 ng/ml; these measurements were also 
used to determine PSA doubling  time20. The nmCRPC categorization date was taken to be the date of the first 
rising PSA test (i.e. the second test overall). Patients with any other primary or secondary malignant cancer, 
receipt of a treatment for metastatic disease in their GP history (secondary care prescribing data were not avail-
able), or presence of a metastatic disease morphology code before their second qualifying PSA measurement, 
were excluded from the nmCRPC cohort.
The stringent nmCRPC subset also required an available morphology code explicitly confirming non-meta-
static disease status (in the absence of any codes indicating metastatic disease) up to the point of meeting criteria 
for nmCRPC (from PEDW, up to date of inclusion).
Statistical analysis. Analyses of survival and Kaplan–Meier plotting were performed using R (V4.0.2). 
Logrank tests and Cox proportional hazard models were used to compare time-to-event analyses from diagnosis 
of PC to nmCRPC categorization and from nmCRPC categorization to metastasis or death according to PSA 
doubling time (≤ 10 months, > 10 months) and age groups (≤ 70, > 70– ≤ 75, > 75– ≤ 80, > 80 years). Continuous 
variables are described using means and standard deviation; categorical variables are summarized with fre-
quency counts and proportions.
Ethical approval. This study was approved by the SAIL Information Governance Review Panel (IGRP) 
under project number 0775. Approval for the use of anonymized data in this study (SAIL project number 0775), 
provisioned within the SAIL Databank, was granted by an independent IGRP with membership comprising sen-
ior representatives from the British Medical Association (BMA), the National Research Ethics Service (NRES), 
Public Health Wales and NHS Wales Informatics Service (NWIS). All methods were carried out in accordance 
with the relevant guidelines and regulations.
Written informed consent was not required for this study, as it used anonymized, routinely collected data. 
The use of anonymized data for research is outside the scope of the EU General Data Protection Regulations 
(GDPR) and the UK Data Protection Act.
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Results
Patient demographics and baseline characteristics. Patient demographics and baseline character-
istics are shown in Table 1. Between 01 January 2000 and 31 December 2015, 38,021 men were diagnosed with 
PC, of which 1,465 (3.9%) were further categorized with nmCRPC based on our main cohort definition, and 470 
(1.2%) patients were categorized with nmCRPC using the stringent subset definition (Supplementary Figure S1). 
Compared to the overall PC cohort, the median age of the main nmCRPC cohort was approximately five years 
greater at initial PC diagnosis (70.6 vs 75.6 years), at commencement of ADT (71.8 vs 76.6 years), at the point of 
development of metastatic disease (71.9 vs 78.1 years) and at death (76.9 vs 83.2 years; Table 1).
Patient demographics and baseline characteristics for the stringent nmCRPC cohort are available in Sup-
plementary Table S1.
Incidence of PC and nmCRPC. PC incidence in Wales, defined as the number of patients with a first 
PC diagnosis, increased from 1,739 in 2000 to 2,689 in 2015 (Fig.  1). The nmCRPC incidence in the main 
nmCRPC cohort (defined as the number of patients with a PC diagnosis who have received ADT and who have 
at least three PSA tests which indicate nmCRPC, as per the requirements outlined previously) increased from 
2000–2007 and then remained relatively stable. However, from 2015 onwards the number of new nmCRPC cases 
reduced until only 18 cases were observed in 2017 (Fig. 1). The numbers of patients diagnosed with PC later 
progressing to meeting the inclusion criteria for the main and stringent nmCRPC cohorts reduced considerably 
from 2007 (Fig. 2).
Overall clinical outcomes. For the main nmCRPC cohort, median time from PC diagnosis to nmCRPC 
categorization was 3.07 years (95% confidence intervals [CI] 2.91–3.26; Fig. 3) with only 429 (29.3%) patients 
living with a PC diagnosis for ≥ 5 years before progressing to nmCRPC. The corresponding results for the strin-
gent nmCRPC subset were consistent with the main nmCRPC cohort (Fig. 3).
Patients in the main nmCRPC cohort had a median time from nmCRPC categorization to metastases or 
death of 2.86 years (95% CI 2.67–3.09) and a 28.9% chance of surviving 5 years without metastases or death. 
Table 1.  Patient demographics and baseline characteristics. ADT: androgen deprivation therapy; 
IQR: interquartile range; N/A: not available; nmCRPC: non-metastatic castration-resistant prostate cancer; PC: 
prostate cancer; PSA: prostate-specific antigen; TNM: tumor, node, metastasis. a This result is presented as ‘ < 5’ 
to ensure patient anonymity.
All patients with PC (N = 38,021) Main nmCRPC cohort (n = 1,465)
All patients with PC excluding main nmCRPC 
cohort (n = 36,556)
Age at, median (IQR)
PC diagnosis 70.6 (65.0–76.9) 75.6 (69.2–80.4) 72.7 (65.9–79.6)
Initiation of ADT 71.8 (66.3–77.6) 76.6 (70.9–81.3) 74.3 (68.1–79.2)
nmCRPC diagnosis N/A 79.5 (73.6–84.6) N/A
Development of metastases 71.9 (65.9–77.5) 78.1 (72.3–84.3) 75.4 (68.8–81.5)
Death 76.9 (70.8–83.0) 83.2 (77.0–88.4) 82.0 (75.8–87.1)
Treatment, n (%)
ADT 16,911 (44.5) 1,465 (100.0) 15,446 (42.3)
Orchidectomy 220 (0.6)  < 5 (< 0.1)a  > 215 (~ 0.6)
Prostatectomy 4,361 (11.5) 18 (1.2) 4,343 (11.9)
Radiotherapy 5,341 (14.0) 189 (12.9) 5,152 (14.1)
PSA doubling time
 ≤ 10 months N/A 952 (65.0) N/A
 > 10 months N/A 513 (35.0) N/A
Gleason score
 ≤ 6 9,407 (24.7) 187 (12.8) 9,220 (25.2)
7 6,726 (17.7) 269 (18.4) 6,457 (17.7)
8–10 4,570 (12.0) 347 (23.7) 4,223 (11.6)
Unknown 17,318 (45.6) 662 (45.2) 16,656 (45.3)
TNM score
Tany N0 M0 5,600 (14.7) 64 (4.4) 5,536 (15.1)
Tany N1–2 M0 269 (0.7) N/A 269 (0.7)
Tany Nany M1 619 (1.6) N/A 619 (1.7)
Other 84 (0.2) N/A 84 (0.2)
Unknown 31,449 (82.7) 1,401 (95.6) 30,048 (82.2)
Time in months, median (IQR)
From PC diagnosis to nmCRPC N/A 37.4 (20.3–66.9) N/A
Duration of follow-up from nmCRPC diagnosis N/A 37.6 (19.5–61.3) N/A
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Figure 1.  Incidence of PC and nmCRPC (for individuals diagnosed with PC from 2000–2015). Incidence of PC 
is defined as the number of patients with a first PC diagnosis in each year. Incidence of nmCRPC is the number 
of patients with a PC diagnosis who have received ADT and who have ≥ 3 PSA tests which indicate nmCRPC. 
The date of nmCRPC incidence is the first test showing an increase in PSA, i.e. the second test overall. The third 
PSA test confirms the increase. Incidence of PC has been divided by 10 to allow for easy comparison with the 
incidence of nmCRPC. ADT: androgen depravation therapy; nmCRPC: non-metastatic castration-resistant 
prostate cancer; PC: prostate cancer; PSA: prostate-specific antigen.
Figure 2.  Number of patients diagnosed with PC each year who later progressed to meet inclusion criteria for 
the main and stringent nmCRPC cohorts. The patients in each column of this graph had a PC diagnosis in the 
year specified on the x-axis. nmCRPC: non-metastatic castration-resistant prostate cancer; PC: prostate cancer.
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After 5 years, 332 patients in this cohort were still at risk (were not censored and surviving without metastases 
or death, Fig. 4). Results from the stringent nmCRPC subset were generally comparable to those of the main 
nmCRPC cohort, but with a lower median survival time of 2.65 years (95% CI 2.41–2.95).
Clinical outcomes by PSA doubling time and age group. The effect of PSA doubling time on survival 
to metastases or death in the main nmCRPC cohort was investigated by stratifying patients by PSA doubling 
time (≤ 10 months, > 10 months; Fig. 5a). The median time of survival to metastases or death in the ≤ 10 months 
Figure 3.  Time from initial PC diagnosis to meeting inclusion criteria for the main and stringent nmCRPC 
cohorts. nmCRPC: non-metastatic castration-resistant prostate cancer; PC: prostate cancer.
Figure 4.  Time from meeting inclusion criteria for the main and stringent nmCRPC cohorts to metastases or 
death. nmCRPC: non-metastatic castration-resistant prostate cancer.
6
Vol:.(1234567890)
Scientific Reports |        (2021) 11:22151  | https://doi.org/10.1038/s41598-021-01042-7
www.nature.com/scientificreports/
group was over 3 years shorter than that of the > 10 months group (2.11 years [95% CI 1.92–2.30] vs 5.22 years 
[95% CI 4.87–5.51]). The percentage of patients reaching 5 years without metastases or death was also lower in 
the ≤ 10 months group (16.3% [n = 126] vs 52.4% [n = 206]). A Cox regression model was applied to both survival 
datasets, but testing of the Schoenfeld residuals concluded that the proportional hazard assumption may not 
hold, therefore results should be treated with caution.
Figure 5.  Time to metastases or death, stratified by a) risk group and b) age group. Risk was categorized 
into two groups, defined as those with a PDADT of either ≤ 10 months or > 10 months. PSA: prostate-specific 
antigen; PSADT: prostate-specific antigen doubling time.
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The effect of age on survival to metastases or death was also assessed using a time-to-event analysis (Fig. 5b). 
Using the Logrank test and the Cox regression model, no significant differences were found between age groups.
Discussion
This retrospective analysis used linked healthcare datasets to identify and characterize a cohort of patients with 
nmCRPC in Wales, building upon a limited pool of real-world literature.
The incidence of PC diagnoses rose throughout the study period. Similarly, the incidence of nmCRPC cases 
appeared to increase from 2000, as expected with the natural progression of patients from PC diagnosis to 
nmCRPC. However, from 2015 there was a sharp decrease in nmCRPC incidence, which may have been influ-
enced by increased access to, and utilization of, cross-sectional imaging and bone scintigraphy throughout the 
time period  studied21. When comparing by year of PC diagnosis, the number of patients with PC which went on 
to be categorized as nmCRPC started to decrease from 2007 onwards. This may be partially attributed to patients 
diagnosed in later years of the study not yet reaching nmCRPC.
Wider use of novel imaging techniques as a diagnostic tool in nmCRPC may lead to differing findings in 
future studies of a similar nature. More accurate detection of metastases can be made using novel  imaging22,23, 
which in turn should lead to more accurate diagnoses of nmCRPC and so we can hope to see treatments better 
tailored to patients’ individual needs in future. As such, we may continue to see decreased nmCRPC incidence, 
but better clinical outcomes in those who do receive a diagnosis. Furthermore, increased availability of treatments 
suitable for nmCRPC can be expected to further improve patient outcomes; examples include apalutamide, an 
androgen receptor inhibitor approved by NICE in September 2021, including for the treatment of high-risk 
prostate cancer which no longer responds to hormone  therapy24.
Here, the median time from PC diagnosis to nmCRPC inclusion for the main nmCRPC cohort (3.07 years) 
was comparable to previous reports, which generally fall between 2–3  years3,25. The median time from nmCRPC 
to metastases or death was 2.86 years, with approximately 30% of patients surviving 5 years without metastases 
or death. This finding is similar to that of a population-based study of Swedish patients with  nmCRPC13. A 
higher percentage of men achieving metastasis-free survival for 5 years after nmCRPC was previously reported 
in the population-based SEARCH study, although this appeared not to include men who died before developing 
 metastases11. The study also required available imaging data and had a smaller sample size, which may account 
for survival  differences11.
A time to metastases or death of 2.11 years was reported for patients in this study with a PSA doubling 
time ≤ 10 months, longer than that reported for the equivalent placebo-treated populations in the SPARTAN 
(1.35 years), PROSPER (1.23 years) and ARAMIS trials (1.53 years)8–10. We have compared this study data to pla-
cebo data from the clinical trials because the life-extending treatments evaluated in the trials were not approved 
for clinical use for most of our study period. However, patients from the SPARTAN and ARAMIS trials had a 
median time from initial diagnosis to randomization of approximately 7 years (unreported in the PROSPER 
trial), so many patients in the trial population may have had a much longer time to metastases or death than 
patients in this real-world  cohort9,10.
Another key difference between the patient populations is access to imaging during treatment. In the RCTs, 
comprehensive imaging was carried out at baseline (including computerized tomography [CT] and MRI scans), 
with any patients with detectable metastases  excluded8–10. Patients continued to receive imaging at regular time-
points during trial participation, likely outside of real-world practice patterns. Our study had no imaging inclu-
sion requirements and imaging was only recorded from 2007 onwards. This may have affected the reported 
median time to metastases and death of patients, underlining our initial premise of exploring the real-world 
clinical characteristics and outcomes of nmCRPC.
Although the effect of PSA doubling time on progression to metastases or death was not statistically signifi-
cant, the numerical evidence suggested a trend that supported previous conclusions that a shorter PSA doubling 
time is a predictor of faster disease  progression26,27. Age at PC diagnosis was not shown to have a significant effect 
on patterns of progression to metastases or death in this study (for those with nmCRPC). Previous literature 
in this area is limited, although it has been reported that older age (> 80 years vs < 70 years) in patients with 
nmCRPC may be associated with higher all-cause  mortality13.
This retrospective analysis demonstrated that linked datasets allow for the identification of a substantial 
sample size of patients with nmCRPC based on PSA criteria, which has previously been difficult to establish 
from database records due to a lack of clinical  coding28. The analysis benefited from a long follow-up period, 
capturing the complete journey of many patients from PC diagnosis to metastasis or death. However, retrospec-
tive studies of population-based data can have data quality and availability limitations. For example, very few 
patients had tumor, node and metastasis (TNM) staging data available due to limited coverage, which prevented 
disease staging. We were also unable to confirm metastatic/non-metastatic disease for all patients due to the ces-
sation of morphology code recording in PEDW from 2017. Given that treatment for metastatic disease was not 
approved for most of our study period, GP prescriptions indicating metastatic treatment were also unavailable 
for patients prior to 2013 and secondary care prescribing data were unavailable. Despite these limitations, the 
main nmCRPC cohort was considered to have successfully included patients with nmCRPC, given that results 
from the stringent nmCRPC subset generally aligned with the main cohort.
More general limitations of registry data include duplication of records, which can arise due to the anonymous 
nature of the  data29, or if the same cancer is diagnosed and reported by more than one provider, as is the case if 
a clinician/patient seeks a second  opinion30. Other issues can be the lack of control population, the potential for 
incomplete follow-up and underestimation of the rate of events due to the absence of rigorous monitoring seen 
in  RCTs29. Registry data does, however, allow for a more accurate representation of real-world practice, giving a 
truer reflection of the effectiveness of treatments and outcomes outside of the rigorously monitored environments 
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of RCTs, which do not account for any additional factors influencing clinician judgement and decisions. Further-
more, the large sample size can also provide more generalizable evidence in comparison to  RCTs29, which tend 
to have far smaller sample sizes and strict inclusion criteria, which may include specific treatments, or exclude 
patients with more complex disease or comorbidities.
This study is one of the first to evaluate the presence of nmCRPC in a real-world, UK-based setting. Our 
findings provide data on clinical demographics and outcomes in nmCRPC prior to the introduction of novel 
treatments such as apalutamide, darolutamide and enzalutamide and hence the potential scope for therapeutic 
need. Future work is required to assess changes in the clinical management of nmCRPC and the impact of these 
new treatment options on survival outcomes.
Data availability
The datasets generated for this study are drawn from patient records held by the SAIL Databank and will not be 
made publicly available. Data may be accessible upon application to the SAIL databank, subject to SAIL govern-
ance processes. Details of this are available on the SAIL website (https:// saild ataba nk. com/ appli cation- proce ss/).
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